Mesoblast Acquires Exclusive CAR Technology License
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2026
0mins
Source: seekingalpha
- Technology License Acquisition: Mesoblast has acquired an exclusive global license for a chimeric antigen receptor (CAR) technology platform developed by Mayo Clinic through the purchase of a startup, which is expected to significantly enhance the efficacy of its products, particularly in treating ulcerative colitis and Crohn's disease.
- Equity Financing: The acquisition was financed through the issuance of ASX ordinary shares, demonstrating the company's flexibility in capital operations while providing funding support for future technology development, thereby boosting market confidence.
- Enhanced Product Efficacy: Mesoblast indicated that the new CAR technology will improve the effectiveness of its mesenchymal lineage stromal cell (MSC) therapies, potentially offering stronger treatment outcomes for patients and enhancing the company's competitive position in the market.
- Support for Technological Advancement: As part of the deal, Mesoblast is committed to providing in-kind support to further advance the CAR technology and resulting products, reflecting the company's emphasis on innovation and commitment to long-term strategic development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MESO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 14.980
Low
35.00
Averages
35.00
High
35.00
Current: 14.980
Low
35.00
Averages
35.00
High
35.00
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Conexeu Sciences Inc. Begins Trading on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking a significant advancement for the preclinical-stage company centered around its CXU™ bioregenerative platform, which is expected to attract more investment for product development.
- Innovative Platform: The CXU™ is a patented bioregenerative extracellular matrix designed to restore soft tissue lost due to injury, aging, and GLP-1-related weight loss, with its first product, Ten Minute Tissue™, demonstrating enhanced healing dynamics and a low inflammatory profile in preclinical studies, potentially garnering significant market interest.
- Market Outlook: Conexeu enters a public market that is showing genuine commercial momentum, with competitors like Integra LifeSciences and Bioventus exceeding expectations in recent earnings reports, indicating strong demand in the regenerative medicine sector, and the listing is likely to enhance Conexeu's market share.
- Strategic Positioning: The listing not only provides Conexeu with the opportunity for capital formation but also enables the advancement of the CXU™ platform across multiple product lines, with plans to submit a 510(k) application in early 2027, further solidifying its position in the regenerative medicine field.
See More
Conexeu Sciences Inc. Successfully Debuts on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking its entry into public markets as a regenerative tissue platform company, which is expected to drive business growth in wound care and aesthetic medicine sectors.
- Platform Advantage: The company's CXU™ extracellular matrix platform is designed to scale across multiple markets without reformulation, a structural advantage that sets it apart from early-stage regenerative medicine companies and may lay the groundwork for future market share expansion.
- Innovative Reconstruction Method: Conexeu's B.R.E.A.S.T.™ matrix is a 3D bioprinted scaffold designed to support the body's own tissue regeneration rather than serve as a permanent implant, representing a potential paradigm shift for over 100,000 U.S. women undergoing mastectomies annually.
- Intellectual Property Protection: Conexeu holds issued patents across the U.S., E.U., Japan, and Australia with no royalty or licensing obligations, providing the freedom to expand into new indications and potentially accelerating its 510(k) submission process.
See More
Mesoblast Reports Strong Q1 Sales for Ryoncil®
- Strong Sales Performance: Mesoblast reported gross sales of $35.3 million and net revenues of $30.3 million for Q1, with robust sales in February and March offsetting January's holiday seasonality, indicating improved market acceptance of Ryoncil®.
- Near $100 Million Annual Revenue: Revenue generated during the first year of Ryoncil® launch approaches $100 million, demonstrating the product's rapid growth potential in the market, which could solidify the company's future financial performance.
- Optimized Cash Flow Management: The net operating cash spend for the quarter was $4.1 million, primarily driven by receipts of $34.6 million and tight control over operating expenses, showcasing the company's effectiveness in financial management.
- Strong Cash Reserves: As of March 31, 2026, Mesoblast had $122 million in cash reserves, providing ample funding for future R&D and market expansion, thereby enhancing investor confidence in the company's long-term growth prospects.
See More
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial
- Ryoncil® Sales Surge: Ryoncil® achieved gross sales of $35.3 million and net revenues of $30.3 million in Q3 FY2026, indicating total revenues nearing $100 million since its launch last year, reflecting strong market demand and product acceptance.
- Optimized Cash Flow Management: The net operating cash spend for the quarter was $4.1 million, significantly reduced due to $34.6 million in receipts and tight control of operating expenses, enhancing the company's financial stability.
- Clinical Trial Progress: Mesoblast successfully met its patient recruitment target in the pivotal Phase 3 trial for the second-generation product rexlemestrocel-L for chronic low back pain, laying the groundwork for future product launches and potentially solidifying the company's market leadership in this area.
- Acquisition and Innovation: The company acquired a patented chimeric antigen receptor (CAR) technology platform aimed at enhancing the potency of therapeutic mesenchymal stem cell products, which is expected to provide more effective treatments for ulcerative colitis and Crohn's disease, further solidifying Mesoblast's innovative leadership in cell therapy.
See More
Mesoblast Achieves Patient Recruitment Target in Chronic Low Back Pain Trial
- Financial Highlights: In the quarter ending March 31, 2026, Mesoblast reported Ryoncil® gross sales of $35.3 million and net revenues of $30.3 million, indicating a strong market performance with total revenues approaching $100 million since last year's launch, showcasing significant growth potential.
- Trial Success: The company successfully achieved its patient recruitment target in the pivotal Phase 3 trial for chronic low back pain, which not only lays the groundwork for subsequent clinical trials but also accelerates the potential market entry of new therapies, enhancing competitive positioning in this therapeutic area.
- Technology Acquisition: Mesoblast acquired an exclusive global license for genetically modified technology aimed at enhancing the precision of cell therapy products, a strategic move that is expected to strengthen its market position in treating inflammatory diseases and potentially yield higher therapeutic efficacy.
- R&D Day Event: During the inaugural R&D day on April 8, Mesoblast highlighted its label extension strategy for Ryoncil® in adult and pediatric rare diseases, emphasizing its leadership in cell therapy innovation, which is anticipated to drive future revenue growth.
See More
Mesoblast Announces RYONCIL® Net Revenues of $30.3 Million and Reduced Net Operating Cash Expenditure of $4.1 Million for the Quarter
- Revenue Report: The company reported revenues of US$30.3 million for the quarter.
- Operating Cash Spend: There was an improved net operating cash spend of US$4.1 million for the same period.
See More
Conexeu Sciences Inc. Begins Trading on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking a significant advancement for the preclinical-stage company centered around its CXU™ bioregenerative platform, which is expected to attract more investment for product development.
- Innovative Platform: The CXU™ is a patented bioregenerative extracellular matrix designed to restore soft tissue lost due to injury, aging, and GLP-1-related weight loss, with its first product, Ten Minute Tissue™, demonstrating enhanced healing dynamics and a low inflammatory profile in preclinical studies, potentially garnering significant market interest.
- Market Outlook: Conexeu enters a public market that is showing genuine commercial momentum, with competitors like Integra LifeSciences and Bioventus exceeding expectations in recent earnings reports, indicating strong demand in the regenerative medicine sector, and the listing is likely to enhance Conexeu's market share.
- Strategic Positioning: The listing not only provides Conexeu with the opportunity for capital formation but also enables the advancement of the CXU™ platform across multiple product lines, with plans to submit a 510(k) application in early 2027, further solidifying its position in the regenerative medicine field.
See More
Conexeu Sciences Inc. Successfully Debuts on Nasdaq
- Listing Milestone: Conexeu Sciences Inc. commenced trading on Nasdaq on May 21, 2026, marking its entry into public markets as a regenerative tissue platform company, which is expected to drive business growth in wound care and aesthetic medicine sectors.
- Platform Advantage: The company's CXU™ extracellular matrix platform is designed to scale across multiple markets without reformulation, a structural advantage that sets it apart from early-stage regenerative medicine companies and may lay the groundwork for future market share expansion.
- Innovative Reconstruction Method: Conexeu's B.R.E.A.S.T.™ matrix is a 3D bioprinted scaffold designed to support the body's own tissue regeneration rather than serve as a permanent implant, representing a potential paradigm shift for over 100,000 U.S. women undergoing mastectomies annually.
- Intellectual Property Protection: Conexeu holds issued patents across the U.S., E.U., Japan, and Australia with no royalty or licensing obligations, providing the freedom to expand into new indications and potentially accelerating its 510(k) submission process.
See More
Mesoblast Reports Strong Q1 Sales for Ryoncil®
- Strong Sales Performance: Mesoblast reported gross sales of $35.3 million and net revenues of $30.3 million for Q1, with robust sales in February and March offsetting January's holiday seasonality, indicating improved market acceptance of Ryoncil®.
- Near $100 Million Annual Revenue: Revenue generated during the first year of Ryoncil® launch approaches $100 million, demonstrating the product's rapid growth potential in the market, which could solidify the company's future financial performance.
- Optimized Cash Flow Management: The net operating cash spend for the quarter was $4.1 million, primarily driven by receipts of $34.6 million and tight control over operating expenses, showcasing the company's effectiveness in financial management.
- Strong Cash Reserves: As of March 31, 2026, Mesoblast had $122 million in cash reserves, providing ample funding for future R&D and market expansion, thereby enhancing investor confidence in the company's long-term growth prospects.
See More
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial
- Ryoncil® Sales Surge: Ryoncil® achieved gross sales of $35.3 million and net revenues of $30.3 million in Q3 FY2026, indicating total revenues nearing $100 million since its launch last year, reflecting strong market demand and product acceptance.
- Optimized Cash Flow Management: The net operating cash spend for the quarter was $4.1 million, significantly reduced due to $34.6 million in receipts and tight control of operating expenses, enhancing the company's financial stability.
- Clinical Trial Progress: Mesoblast successfully met its patient recruitment target in the pivotal Phase 3 trial for the second-generation product rexlemestrocel-L for chronic low back pain, laying the groundwork for future product launches and potentially solidifying the company's market leadership in this area.
- Acquisition and Innovation: The company acquired a patented chimeric antigen receptor (CAR) technology platform aimed at enhancing the potency of therapeutic mesenchymal stem cell products, which is expected to provide more effective treatments for ulcerative colitis and Crohn's disease, further solidifying Mesoblast's innovative leadership in cell therapy.
See More
Mesoblast Achieves Patient Recruitment Target in Chronic Low Back Pain Trial
- Financial Highlights: In the quarter ending March 31, 2026, Mesoblast reported Ryoncil® gross sales of $35.3 million and net revenues of $30.3 million, indicating a strong market performance with total revenues approaching $100 million since last year's launch, showcasing significant growth potential.
- Trial Success: The company successfully achieved its patient recruitment target in the pivotal Phase 3 trial for chronic low back pain, which not only lays the groundwork for subsequent clinical trials but also accelerates the potential market entry of new therapies, enhancing competitive positioning in this therapeutic area.
- Technology Acquisition: Mesoblast acquired an exclusive global license for genetically modified technology aimed at enhancing the precision of cell therapy products, a strategic move that is expected to strengthen its market position in treating inflammatory diseases and potentially yield higher therapeutic efficacy.
- R&D Day Event: During the inaugural R&D day on April 8, Mesoblast highlighted its label extension strategy for Ryoncil® in adult and pediatric rare diseases, emphasizing its leadership in cell therapy innovation, which is anticipated to drive future revenue growth.
See More
Mesoblast Announces RYONCIL® Net Revenues of $30.3 Million and Reduced Net Operating Cash Expenditure of $4.1 Million for the Quarter
- Revenue Report: The company reported revenues of US$30.3 million for the quarter.
- Operating Cash Spend: There was an improved net operating cash spend of US$4.1 million for the same period.
See More
